Cargando…
Informing iQOS Regulations in the United States: A Synthesis of What We Know
The tobacco industry offers various products, including heated tobacco products (HTPs). Philip Morris International’s (PMI) “iQOS” has the greatest HTP market share, as well as research on its use and impact. iQOS was released in 2014 and is now in more than 40 countries. The U.S. Food and Drug Admi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384757/ https://www.ncbi.nlm.nih.gov/pubmed/32719733 http://dx.doi.org/10.1177/2158244019898823 |
_version_ | 1783563661008175104 |
---|---|
author | Berg, Carla J. Bar-Zeev, Yael Levine, Hagai |
author_facet | Berg, Carla J. Bar-Zeev, Yael Levine, Hagai |
author_sort | Berg, Carla J. |
collection | PubMed |
description | The tobacco industry offers various products, including heated tobacco products (HTPs). Philip Morris International’s (PMI) “iQOS” has the greatest HTP market share, as well as research on its use and impact. iQOS was released in 2014 and is now in more than 40 countries. The U.S. Food and Drug Administration announced permission for PMI to sell iQOS in the United States in April 2019, and iQOS was launched in October 2019. Decisions pending its modified risk tobacco product (MRTP) application will occur subsequently. The U.S. regulatory efforts regarding iQOS could be informed by examining (a) Philip Morris USA other product marketing efforts and (b) the iQOS market in countries where it is available. This article briefly addresses these two points with extant literature and suggests that future research should address important gaps in what is currently known, including strategic international collaborations and research, which historically has been critical for advancing tobacco control globally. |
format | Online Article Text |
id | pubmed-7384757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
record_format | MEDLINE/PubMed |
spelling | pubmed-73847572020-07-27 Informing iQOS Regulations in the United States: A Synthesis of What We Know Berg, Carla J. Bar-Zeev, Yael Levine, Hagai Sage Open Article The tobacco industry offers various products, including heated tobacco products (HTPs). Philip Morris International’s (PMI) “iQOS” has the greatest HTP market share, as well as research on its use and impact. iQOS was released in 2014 and is now in more than 40 countries. The U.S. Food and Drug Administration announced permission for PMI to sell iQOS in the United States in April 2019, and iQOS was launched in October 2019. Decisions pending its modified risk tobacco product (MRTP) application will occur subsequently. The U.S. regulatory efforts regarding iQOS could be informed by examining (a) Philip Morris USA other product marketing efforts and (b) the iQOS market in countries where it is available. This article briefly addresses these two points with extant literature and suggests that future research should address important gaps in what is currently known, including strategic international collaborations and research, which historically has been critical for advancing tobacco control globally. 2020-01-09 2020 /pmc/articles/PMC7384757/ /pubmed/32719733 http://dx.doi.org/10.1177/2158244019898823 Text en Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Article Berg, Carla J. Bar-Zeev, Yael Levine, Hagai Informing iQOS Regulations in the United States: A Synthesis of What We Know |
title | Informing iQOS Regulations in the United States: A Synthesis of What We Know |
title_full | Informing iQOS Regulations in the United States: A Synthesis of What We Know |
title_fullStr | Informing iQOS Regulations in the United States: A Synthesis of What We Know |
title_full_unstemmed | Informing iQOS Regulations in the United States: A Synthesis of What We Know |
title_short | Informing iQOS Regulations in the United States: A Synthesis of What We Know |
title_sort | informing iqos regulations in the united states: a synthesis of what we know |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384757/ https://www.ncbi.nlm.nih.gov/pubmed/32719733 http://dx.doi.org/10.1177/2158244019898823 |
work_keys_str_mv | AT bergcarlaj informingiqosregulationsintheunitedstatesasynthesisofwhatweknow AT barzeevyael informingiqosregulationsintheunitedstatesasynthesisofwhatweknow AT levinehagai informingiqosregulationsintheunitedstatesasynthesisofwhatweknow |